The problem of pleiotropic drug resistance in cancer Adriamycin (ADM, Farmitalia) and vincristine (VCR, Eli chemotherapy may be tackled in a number of ways. One of Lilley) were dissolved in sterile distilled water and added to these involves the use of additional chemical agents 5 ml of growth medium in a volume of 50 ul. Cyclosporins (resistance modifiers) which partially or fully restore (Cs) A, C, G and H were kindly supplied by Sandoz Ltd cytotoxic drug sensitivity to resistant cells. Among agents (Basle) . The structures of these compounds are shown in shown to possess this property are calcium transport Figure 1 , and their antifugal and immunosuppressive blockers (e.g. verapamil) (Tsuruo et al., 1981 (Tsuruo et al., , 1982 (Tsuruo et al., , 1983 ; properties summarised in Table I . The cyclosporins were Slater et al., 1982; Twentyman et al., 1986a and calmodulin initially dissolved in absolute ethanol. They were then diluted inhibitors (e.g. trifluoperazine) (Tsuruo et al., 1982 (Tsuruo et al., , 1983 . It 1: 10 in medium and finally added to 5 ml of growth medium has recently been shown that the immunosuppressive drug, in a volume of 50p1, thereby producing a final ethanol cyclosporin A, binds to calmodulin (Colombani et al., 1985) , concentration of 0.1%. This concentration of ethanol does can potentiate the effects of adriamycin and etoposide not affect cell growth or drug sensitivity. in L1210 cells (Osieka et al., 1986) , and is also able to Typical response data for H69/P and H69/LX4 cells function as a modifier of resistance to daunorubicin and treated with ADM in the presence or absence of CsA are vincristine in Ehrlich ascites carcinoma in vivo and in acute shown in Figure 2 . Data from several experiments where lymphatic leukaemia in vitro (Slater et al., 1986a,b) . In this ADM was combined with CsA at a dose of 5 pugml-I are paper we describe studies carried out using a multi-drug shown in Table II and data for VCR combined with CsA in resistant variant of a human small cell lung cancer line. The Table III . It can be seen that the addition of CsA at a dose ability of cyclosporin A and a number of analogues to of 5 jug ml-1 led to a small increase in the sensitivity of overcome resistance to adriamycin and vincristine is H69/P to both cytotoxic drugs, whereas a very large increase investigated.
in the sensitivity of H69/LX4 cells was seen. Sensitisation of The derivation and characteristics of a multi-drug resistant H69/LX4 cells to ADM is clearly dependent upon the dose variant (NCI-H69/LX4) of the human small cell lung cancer of CsA (Table II) the cells during continuous drug exposure as previously described (Twentyman et al., 1986b 
which time the original cell number had increased 10-fold. In most experiments, two replicate dishes were used in the control growth and a single dish at each of 6 or 7 different Table II. RF (resistance factor)=--------ID80 for H69/P Sensitisation of H69/LX4 to VCR (Table III) was also line, the observations reported by Slater et al., (1986a, b) Table II. be seen at 0.5-1.0ygml-1 of CsA, but it requires 5pgml-P to reduce the resistance factor by a factor of 20. Our previous studies using verapamil have shown that a verapamil dose of 6.6 pM (3.3 jg ml-1) is required to produce a similar modification of ADM resistance in H69/LX4 (Twentyman et al., 1986a) . The maximum clinically achievable plasma concentration of verapamil without excessive toxicity is 1-2 jg ml-I (Rogan et al., 1984) , and peak CsA concentrations of 1-2 jg ml-1 are observed following immunosuppressive administration (Kahan et al., 1983) . It would therefore appear that CsA is approximately an equal candidate to verapamil for clinical use judged solely on this basis. Examination of the resistance-modifying properties of the 3 CsA analogues indicates a close correlation with their immunosuppressive efficiency. If both of these functions are dependent upon the ability of cyclosporins to inhibit calmodulin acitivity then this is the result that would be expected. Other factors could, however, be involved such as the ability of different cyclosporins to enter the cell. A quite different mechanism of resistance modification has, on the other hand, been proposed by Slater et al. (1986b) who suggests that CsA may promote cytotoxic drug action at the membrane level by altering the biophysical properties of the plasma membrane. Studies of the effects of cyclosporins upon the cellular pharmacokinetics of ADM and VCR currently in progress in our laboratory should help to elucidate the mechanism of sensitisation.
The adminstration of an immunosuppressive agent to a cancer patient in the hope of overcoming cytotoxic drug resistance is clearly problematic. It is important to determine if analogues of CsA exist which are able to act as resistance modifiers in the absence of immunosuppressive properties. We are currently investigating a range of, additional analogues which should help to clarify the relationship between these properties.
